



Corrigendum: Adrenoleukodystrophy Newborn Screening in the Netherlands (SCAN Study): The X-Factor

Rinse W. Barendsen^{1,2}, Inge M. E. Dijkstra¹, Wouter F. Visser³, Mariëlle Alders⁴, Jet Bliëk⁴, Anita Boelen⁵, Marelle J. Bouva⁶, Saskia N. van der Crabben⁴, Ellen Elsinghorst⁷, Ankie G. M. van Gorp⁷, Annemieke C. Heijboer^{5,8}, Mandy Jansen⁹, Yorrick R. J. Jaspers¹, Henk van Lenthe¹, Ingrid Metgod^{5,8}, Christiaan F. Mooij¹⁰, Elise H. C. van der Sluijs¹, A. S. Paul van Trotsenburg¹⁰, Rendelien K. Verschoof-Puite⁹, Frédéric M. Vaz¹, Hans R. Waterham¹, Frits A. Wijburg², Marc Engelen¹¹, Eugène Dekkers⁷ and Stephan Kemp^{1,11*}

¹ Department of Clinical Chemistry, Laboratory Genetic Metabolic Diseases, Amsterdam UMC, Amsterdam Gastroenterology and Metabolism, University of Amsterdam, Amsterdam, Netherlands, ² Pediatric Metabolic Diseases, Amsterdam UMC, Emma Children's Hospital, University of Amsterdam, Amsterdam, Netherlands, ³ Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands, ⁴ Department of Clinical Genetics, Amsterdam UMC, Amsterdam Reproduction & Development, University of Amsterdam, Amsterdam, Netherlands, ⁵ Department of Clinical Chemistry, Neonatal Screening Laboratory, Endocrine Laboratory, Amsterdam UMC, Amsterdam Gastroenterology and Metabolism, University of Amsterdam, Amsterdam, Netherlands, ⁶ Reference Laboratory for Neonatal Screening, Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands, ⁷ Centre for Population Screening, National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands, ⁸ Department of Clinical Chemistry, Endocrine Laboratory, Amsterdam UMC, Amsterdam Gastroenterology and Metabolism, Vrije Universiteit Amsterdam, Amsterdam, Netherlands, ⁹ Department for Vaccine Supply and Prevention Programmes, National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands, ¹⁰ Department of Pediatric Endocrinology, Amsterdam UMC, Emma Children's Hospital, University of Amsterdam, Amsterdam, Netherlands, ¹¹ Department of Pediatric Neurology, Amsterdam UMC, Amsterdam Leukodystrophy Center, Emma Children's Hospital, Amsterdam Neuroscience, University of Amsterdam, Amsterdam, Netherlands

OPEN ACCESS

Edited and reviewed by:

Maya Schuldiner,
Weizmann Institute of Science, Israel

*Correspondence:

Stephan Kemp
s.kemp@amsterdamumc.nl

Specialty section:

This article was submitted to
Membrane Traffic,
a section of the journal
Frontiers in Cell and Developmental
Biology

Received: 20 November 2020

Accepted: 11 January 2021

Published: 28 January 2021

Citation:

Barendsen RW, Dijkstra IME, Visser WF, Alders M, Bliëk J, Boelen A, Bouva MJ, van der Crabben SN, Elsinghorst E, van Gorp AGM, Heijboer AC, Jansen M, Jaspers YRJ, van Lenthe H, Metgod I, Mooij CF, van der Sluijs EHC, van Trotsenburg ASP, Verschoof-Puite RK, Vaz FM, Waterham HR, Wijburg FA, Engelen M, Dekkers E and Kemp S (2021) Corrigendum: Adrenoleukodystrophy Newborn Screening in the Netherlands (SCAN Study): The X-Factor. *Front. Cell Dev. Biol.* 9:631655. doi: 10.3389/fcell.2021.631655

Keywords: adrenoleukodystrophy, peroxisomes, newborn screening, neonatal, gender, heel prick, dried bloodspots, X chromosome

A Corrigendum on

Adrenoleukodystrophy Newborn Screening in the Netherlands (SCAN Study): The X-Factor by Barendsen, R. W., Dijkstra, I. M. E., Visser, W. F., Alders, M., Bliëk, J., Boelen, A., et al. (2020). *Front. Cell Dev. Biol.* 8:499. doi: 10.3389/fcell.2020.00499

In the original article, there was a mistake in the legend for **Figure 6** as published. Three numbers were not in superscript which changed concentrations and there was an error in dosage. The correct legend appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Figure 6 | Our patient- and parent-friendly, multidisciplinary, centralized follow-up protocol. ¹All follow-up appointments will be scheduled on the same day (Wednesday); ²Before 10:00 AM; ³15 µg/kg/dose, max. 125 µg/dose; ⁴10 µg/dL = 276 nmol/L, 18 µg/dL = 497 nmol/L; ⁵10 mg/m²/day in three equal doses (3 times per day 33.3% of the total daily dose); when older than 6 months: 50% early in the morning, and 25% early in the afternoon and evening. Adrenal surveillance protocol adapted and modified from Regelman et al. (2018). Abbreviations:

ACTH, adrenocorticotrophic hormone; K, potassium; Na, sodium;
PRA, plasma renin activity; Q&A, questions & answers.

REFERENCES

Regelmann, M. O., Kamboj, M. K., Miller, B. S., Nakamoto, J. M., Sarafoglou, K., Shah, S., et al. (2018). Adrenoleukodystrophy: guidance for adrenal surveillance in males identified by newborn screen. *J. Clin. Endocrinol. Metab.* 103, 4324–4331. doi: 10.1210/jc.2018-00920

Copyright © 2021 Barendsen, Dijkstra, Visser, Alders, Blik, Boelen, Bouva, van der Crabben, Elsingerhorst, van Gorp, Heijboer, Jansen, Jaspers, van Lenthe, Metgod, Mooij, van der Sluijs, van Trotsenburg, Verschoof-Puite, Vaz, Waterham, Wijburg, Engelen, Dekkers and Kemp. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.